Derazantinib - CAS# 1234356-69-4 6049 SB-334867 was the first non-peptide

SB-334867 was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX1

which is relatively rare in the total population

Odanacatib for the treatment of postmenopausal osteoporosis

Molecular Weight: 353

calcium/calmodulin-dependent protein kinase 1 and smooth muscle myosin light-chain kinase

Derazantinib - CAS# 1234356-69-4 6049 SB-334867 was the first non-peptideDerazantinib, CAS No. 1234356 69 4, also known as ARQ 087, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor ARQ 087 binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR overexpressing tumor